SESN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SESN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Sesen Bio's Capital Expenditure for the three months ended in Dec. 2022 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2022 was $2.68 Mil.
Hence, Sesen Bio's Capex-to-Operating-Cash-Flow for the three months ended in Dec. 2022 was 0.00.
The historical data trend for Sesen Bio's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sesen Bio Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Sesen Bio Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Sesen Bio's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sesen Bio's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sesen Bio's Capex-to-Operating-Cash-Flow falls into.
Sesen Bio's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2022 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (0) | / | 24.895 | |
= | 0.00 |
Sesen Bio's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2022 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (0) | / | 2.681 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sesen Bio (NAS:SESN) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of Sesen Bio's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Modernatx, Inc. | 10 percent owner | 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Sanford S Zweifach | director | 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021 |
Steven Kelly | director, officer: President and CEO | C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Briggs Morrison | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451 |
Richard Steven Morris | officer: Chief Financial Officer | 397 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
Chidozie Ugwumba | director | 158 FILMORE STREET, DENVER CO 80206 |
Bjorn Odlander | director | C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51 |
Michael Klichinsky | officer: Chief Scientific Officer | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Michael Torok | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Regina Hodits | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Elly Ryu | officer: Principal Accounting Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Glen C Macdonald | officer: Chief Technology Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Monica Forbes | officer: Chief Financial Officer | 3344 NORTH TORREY PINES CT., SUITE 200, SAN DIEGO CA 92037 |
Thomas R Cannell | director, officer: President and CEO | C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Mark Sullivan | officer: General Counsel & Secretary | 1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054 |
From GuruFocus
By Business Wire Business Wire • 01-30-2023
By Business Wire Business Wire • 02-02-2023
By Business Wire Business Wire • 11-29-2021
By Business Wire Business Wire • 02-16-2023
By PRNewswire • 08-10-2023
By Business Wire Business Wire • 02-15-2023
By Business Wire Business Wire • 12-29-2022
By Business Wire Business Wire • 01-04-2023
By Marketwired Marketwired • 10-17-2021
By PRNewswire PRNewswire • 10-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.